Dietary supplement use is often not reported to health care teams
the ONA take:
Research from Boston Medical Center found that some clinicians are not asking patients about their dietary supplement use, some patients do not disclose their use of them, and dietary supplement use is often not included in medical documentation.
This can challenge the effectiveness of prescription regimens and lead to serious repercussions for patients.
Researchers recently found an amphetamine-like stimulant in dietary supplements. As a result, stores such as the Vitamin Shoppe pulled as many as 25 supplements off their shelves because they contained the ingredient, which was linked to a woman’s stroke.
Another recent study found a number of supplements may even increase the risk of developing certain cancers.
Patients may not know that their health care team needs this information when planning their care or fear being judged for their use of the products.
The researchers conclude that clinicians need to be more conscious of and better educated on the importance of talking with patients of all ages and cultural backgrounds about dietary supplement use.
Some patients do not disclose their use of them, and dietary supplement use is often not included in medical documentation.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|